Virax Biolabs Group (VRAX) Competitors $1.05 -0.04 (-3.67%) Closing price 03:57 PM EasternExtended Trading$1.06 +0.01 (+1.05%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. SPRB, INAB, QNTM, SYBX, AFMD, MEIP, IMNN, CLDI, ORGS, and SLGLShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Spruce Biosciences (SPRB), IN8bio (INAB), Quantum Biopharma (QNTM), Synlogic (SYBX), Affimed (AFMD), MEI Pharma (MEIP), Imunon (IMNN), Calidi Biotherapeutics (CLDI), Orgenesis (ORGS), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Spruce Biosciences IN8bio Quantum Biopharma Synlogic Affimed MEI Pharma Imunon Calidi Biotherapeutics Orgenesis Sol-Gel Technologies Virax Biolabs Group (NASDAQ:VRAX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment. Which has higher valuation & earnings, VRAX or SPRB? Virax Biolabs Group has higher earnings, but lower revenue than Spruce Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$84.87K40.00-$6.73MN/AN/ASpruce Biosciences$4.91M1.12-$47.92M-$1.28-0.10 Which has more risk and volatility, VRAX or SPRB? Virax Biolabs Group has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Is VRAX or SPRB more profitable? Virax Biolabs Group has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Virax Biolabs Group's return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Spruce Biosciences -555.23%-62.10%-47.49% Do analysts prefer VRAX or SPRB? Virax Biolabs Group presently has a consensus price target of $3.00, suggesting a potential upside of 185.71%. Spruce Biosciences has a consensus price target of $2.17, suggesting a potential upside of 1,569.23%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to VRAX or SPRB? In the previous week, Spruce Biosciences had 3 more articles in the media than Virax Biolabs Group. MarketBeat recorded 5 mentions for Spruce Biosciences and 2 mentions for Virax Biolabs Group. Spruce Biosciences' average media sentiment score of 0.85 beat Virax Biolabs Group's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virax Biolabs Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VRAX or SPRB? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor VRAX or SPRB? Spruce Biosciences received 38 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. However, 100.00% of users gave Virax Biolabs Group an outperform vote while only 54.17% of users gave Spruce Biosciences an outperform vote. CompanyUnderperformOutperformVirax Biolabs GroupOutperform Votes1100.00% Underperform VotesNo VotesSpruce BiosciencesOutperform Votes3954.17% Underperform Votes3345.83% SummaryVirax Biolabs Group beats Spruce Biosciences on 9 of the 16 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.40M$2.45B$5.44B$7.80BDividend YieldN/A0.79%5.43%4.31%P/E RatioN/A7.2422.1418.40Price / Sales40.0054.50389.70101.29Price / CashN/A15.7538.2034.62Price / Book0.533.716.664.18Net Income-$6.73M-$65.73M$3.21B$247.71M7 Day Performance5.69%10.06%5.83%6.45%1 Month Performance-18.60%-10.52%-4.32%-3.14%1 Year Performance50.00%-8.09%17.83%5.40% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group2.6611 of 5 stars$1.05-3.7%$3.00+185.7%+67.4%$3.40M$84,872.000.005News CoverageSPRBSpruce Biosciences3.0236 of 5 stars$0.31+8.0%$2.50+695.2%-80.1%$12.99M$7.10M-0.3320Positive NewsGap UpINABIN8bio3.0666 of 5 stars$0.16+4.7%$6.00+3,668.8%-82.5%$12.94MN/A-0.2120QNTMQuantum BiopharmaN/A$6.72-3.2%N/AN/A$12.90MN/A-0.44N/AGap DownSYBXSynlogic1.0563 of 5 stars$1.10+7.3%N/A-38.3%$12.87M$8,000.00-0.2680Gap DownAFMDAffimed3.8043 of 5 stars$0.79+27.2%$13.50+1,606.9%-81.8%$12.73M$877,000.000.00200Analyst ForecastMEIPMEI Pharma2.1666 of 5 stars$1.91+2.1%N/A-33.9%$12.73M$65.30M-0.33100Analyst ForecastIMNNImunon1.9055 of 5 stars$0.87+2.4%$21.50+2,371.3%-31.1%$12.72M$500,000.00-0.4630CLDICalidi Biotherapeutics1.7123 of 5 stars$0.43-1.4%$15.00+3,357.0%N/A$12.35M$50,000.000.0038News CoverageORGSOrgenesisN/A$2.50+26.9%N/AN/A$12.00M$662,000.000.00150SLGLSol-Gel Technologies1.7771 of 5 stars$0.43-0.4%$5.00+1,067.1%-15.7%$11.93M$11.71M-1.2650 Related Companies and Tools Related Companies Spruce Biosciences Competitors IN8bio Competitors Quantum Biopharma Competitors Synlogic Competitors Affimed Competitors MEI Pharma Competitors Imunon Competitors Calidi Biotherapeutics Competitors Orgenesis Competitors Sol-Gel Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRAX Stock Free VRAX Stock Alerts